How to protect muscle while losing weight on GLP-1s

GLP-1 drugs can drive significant weight loss, but some of that loss is lean mass, not just fat. Here is what the trial data actually shows, what remains uncertain, and what you can do about it.

The two landmark trials that established GLP-1 medications as major tools for weight management were large, well-designed studies. In the STEP 1 trial, participants taking semaglutide lost an average of 14.9% of their body weight over 68 weeks, compared to 2.4% with placebo. In the SURMOUNT-1 trial, participants taking tirzepatide lost an average of 15 to 20.9% of their body weight over 72 weeks, compared to 3.1% with placebo. What these trials were primarily designed to measure, however, was total body weight and cardiometabolic markers: blood pressure, blood sugar, and cholesterol. Body composition (the breakdown of weight loss into fat mass versus lean mass) was not the primary focus. Some body composition data does exist within these datasets, typically from smaller substudies using DEXA scanning, a type of imaging that can estimate fat and lean tissue. But these substudies involved a fraction of the total trial participants, and the results should be interpreted carefully. Small sample sizes within larger trials can produce estimates that don't hold up when studied more broadly. We have good data on how much weight people lose on GLP-1 medications. We have much less data on exactly what kind of weight they are losing.

Losing some lean mass during significant weight loss is normal and expected, regardless of the method used. When the body is in a sustained caloric deficit, it draws on multiple energy sources, and lean tissue is among them. This happens with diet alone, with bariatric surgery, and with other weight-loss medications. The more relevant question is not whether GLP-1 users lose lean mass (they do) but whether they lose a greater proportion of lean mass compared to people losing similar amounts of weight through other means. That question does not yet have a clear answer, because head-to-head body composition trials comparing GLP-1 medications to other interventions have not been done. One area of active research involves combining GLP-1 medications with other agents that may shift the ratio of fat to lean mass loss. A phase 2 trial published in Nature Medicine examined the combination of bimagrumab (an investigational drug that targets muscle and fat pathways) with semaglutide. Participants taking the combination lost more weight overall (−17.8 kg at 48 weeks) than those on either drug alone, and the combination appeared to affect body composition in ways that favored fat loss over lean mass loss. This is an interesting early signal; it is also phase 2 data from a single trial, which means it is far too early to draw firm conclusions or to consider this a clinical option. It is mentioned here because it illustrates that researchers are actively working on this question, not because it changes current practice. We do not yet have enough head-to-head body composition data to say definitively whether GLP-1 medications are better or worse than alternatives at preserving lean mass. The concern is real, the research is ongoing, and the field is moving quickly.

In the broader weight-loss literature (meaning studies of people losing weight through calorie restriction, not specifically through GLP-1 medications) higher protein intake is consistently associated with better preservation of lean mass. The proposed mechanism is straightforward: protein provides the amino acids that muscle tissue needs to maintain and repair itself, and when overall food intake drops, getting enough protein becomes harder. It is reasonable to think this principle applies to people taking GLP-1 medications; there is no biological reason it would not. But reasonable inference is not the same as evidence in this population, and that distinction matters when translating general guidance into specific recommendations. There is a practical wrinkle specific to GLP-1 users: these medications suppress appetite significantly. Many people find that they feel full much sooner than they used to, and eating enough of anything (let alone protein-dense foods) becomes a genuine challenge. Even people who understand the importance of protein may struggle to meet general targets while on these medications. The weight-loss literature discusses a range of protein targets for people in a caloric deficit, but there is no single universally agreed-upon number, and no GLP-1-specific protein trial exists to guide recommendations for this population. Giving you a specific gram-per-day target here would go beyond what the evidence supports. What is appropriate: discussing your current protein intake with your clinician or a registered dietitian, particularly given how your appetite may have changed since starting medication. A dietitian can help you find practical ways to prioritize protein within whatever amount of food you are actually able to eat.

The evidence that resistance training (weightlifting, bodyweight exercises, resistance bands, and similar activities) helps preserve and build lean mass during weight loss is well established in the general population. This is one of the more consistent findings in exercise science. When people lose weight through calorie restriction alone, they tend to lose more lean mass than when they combine calorie restriction with resistance training. What is not yet established is how this applies specifically to people taking GLP-1 medications. No randomized controlled trials have examined resistance training protocols in GLP-1 users. This gap is meaningful for a few reasons: people on GLP-1 medications may experience fatigue, nausea, or reduced energy intake that affects their capacity to exercise (particularly early in treatment); their starting fitness levels vary widely; and the interaction between GLP-1-driven appetite suppression and the energy demands of resistance training is not well characterized. None of this means resistance training is a bad idea for GLP-1 users. The general evidence for its role in lean mass preservation is strong, and it is broadly safe and beneficial for most people. But the specific programming question (how much, how often, what type) remains an open research question for this population. Rather than following a generic protocol, it is worth discussing exercise with your care team. A referral to a physical therapist or certified exercise physiologist can help you develop an approach that fits your current fitness level, any physical limitations you have, and how you actually feel on medication.

Much of this topic is discussed with more confidence than the evidence warrants. Here is a clearer accounting of what we do not yet know. Body composition data from GLP-1 trials is limited. The major trials ran for 68 to 72 weeks. We have no body composition data beyond that timeframe, so what happens to lean mass over years of treatment is unknown. No head-to-head trials exist. We cannot currently say, based on trial data, whether GLP-1 medications are better or worse than diet alone, bariatric surgery, or other medications at preserving lean mass during equivalent weight loss. No protein intake trials in GLP-1 users exist. Protein recommendations for this population are extrapolated from general weight-loss research, not derived from studies of people on these medications. No resistance training RCTs in GLP-1 users exist. The same extrapolation applies to exercise guidance. Emerging combination therapies are early-stage. The bimagrumab-plus-semaglutide data is promising but comes from a single phase 2 trial. It is not a clinical option at this time. Long-term effects on muscle function, strength, and bone density are largely unknown. Losing lean mass is not just a cosmetic concern; muscle supports mobility, balance, and metabolic health. Whether GLP-1-driven weight loss affects these functional outcomes over the long term has not been adequately studied.

Because so much of the guidance in this area is extrapolated rather than GLP-1-specific, the conversation you have with your care team matters more than any generalized protocol. Here are some areas worth raising.

Body composition monitoring

Ask whether tracking something beyond scale weight (such as a DEXA scan) makes sense for your situation. Not everyone needs this, but for some people it provides useful information about whether weight loss is coming from fat, lean mass, or both.

Protein intake

Ask whether your current eating pattern is providing adequate protein given how your appetite has changed. If there is uncertainty, ask whether a referral to a registered dietitian would be helpful.

Exercise

Ask about incorporating resistance training and whether a referral to a physical therapist or exercise physiologist is appropriate for your fitness level and health status.

Pace of weight loss

Faster weight loss is generally associated with greater lean mass loss, though the relationship is not perfectly linear. Ask whether your current rate of loss is appropriate for your goals.

Symptoms to watch for

If you notice significant weakness, unusual fatigue, or a decline in your ability to do everyday physical tasks, raise it explicitly with your clinician rather than assuming these are expected side effects.

Questions to bring to your next appointment:

"How much of my weight loss is likely coming from fat versus muscle?"

"Should I be tracking anything beyond the scale?"

"Is my protein intake adequate given how my appetite has changed?"

"Are there signs I should watch for that would suggest I'm losing too much lean mass?"

"Is my current pace of weight loss appropriate?"

Concern about muscle loss during GLP-1-driven weight loss is not a myth or an overreaction. It is a real and reasonable thing to pay attention to. At the same time, lean mass loss is a feature of significant weight loss by any method, and the evidence does not currently show that GLP-1 medications are uniquely harmful to muscle compared to other approaches. The two strategies with the most general support (adequate protein intake and resistance exercise) are sensible to pursue, but neither has been rigorously tested in people taking GLP-1 medications specifically. Recommendations in this area are extrapolated from broader research, and individual circumstances vary enough that personalized guidance from a clinician or registered dietitian is more useful than any one-size-fits-all protocol. Monitor more than the scale. Stay in conversation with your care team. And as the research in this area continues to develop, expect the guidance to evolve.